Overview

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Status:
Not yet recruiting

Trial end date:
2025-07-21

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation